Source Humanized (from mouse) ATC code none ChemSpider none | Target Complement component 5 Legal status investigational | |
Type Single-chain variable fragment | ||
Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting and angioplasty, among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.
Current status
Alexion, the developer of pexelizumab, stopped development when the phase 3 trial indicated the heart-attack drug is no better than placebo.
References
Pexelizumab Wikipedia(Text) CC BY-SA